Barrow Hanley Mewhinney & Strauss LLC Sells 256,112 Shares of Smith & Nephew SNATS, Inc. $SNN

Barrow Hanley Mewhinney & Strauss LLC cut its position in shares of Smith & Nephew SNATS, Inc. (NYSE:SNN) by 30.6% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 580,206 shares of the medical equipment provider’s stock after selling 256,112 shares during the quarter. Barrow Hanley Mewhinney & Strauss LLC owned approximately 0.14% of Smith & Nephew SNATS worth $21,056,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in SNN. AlphaCore Capital LLC purchased a new stake in Smith & Nephew SNATS in the 2nd quarter valued at about $44,000. Huntington National Bank boosted its stake in shares of Smith & Nephew SNATS by 1,837.0% in the 3rd quarter. Huntington National Bank now owns 1,414 shares of the medical equipment provider’s stock worth $51,000 after buying an additional 1,341 shares during the last quarter. Smartleaf Asset Management LLC boosted its stake in shares of Smith & Nephew SNATS by 1,222.3% in the 3rd quarter. Smartleaf Asset Management LLC now owns 2,486 shares of the medical equipment provider’s stock worth $88,000 after buying an additional 2,298 shares during the last quarter. Root Financial Partners LLC bought a new position in shares of Smith & Nephew SNATS in the third quarter valued at approximately $102,000. Finally, MAI Capital Management grew its holdings in shares of Smith & Nephew SNATS by 24.0% in the second quarter. MAI Capital Management now owns 4,371 shares of the medical equipment provider’s stock valued at $134,000 after acquiring an additional 846 shares in the last quarter. 25.64% of the stock is owned by institutional investors.

Smith & Nephew SNATS Stock Performance

SNN stock opened at $33.34 on Thursday. The company has a current ratio of 2.57, a quick ratio of 1.25 and a debt-to-equity ratio of 0.60. Smith & Nephew SNATS, Inc. has a fifty-two week low of $23.91 and a fifty-two week high of $38.79. The stock has a fifty day moving average of $34.46 and a 200-day moving average of $34.84.

Smith & Nephew SNATS Announces Dividend

The firm also recently announced a dividend, which will be paid on Wednesday, May 27th. Shareholders of record on Friday, March 27th will be given a dividend of $0.482 per share. This represents a yield of 281.0%. The ex-dividend date is Friday, March 27th.

Wall Street Analyst Weigh In

SNN has been the topic of a number of recent analyst reports. Kepler Capital Markets upgraded Smith & Nephew SNATS to a “strong-buy” rating in a report on Monday, November 17th. Royal Bank Of Canada lowered Smith & Nephew SNATS from an “outperform” rating to a “sector perform” rating in a research report on Monday, December 15th. Weiss Ratings reiterated a “hold (c+)” rating on shares of Smith & Nephew SNATS in a research note on Wednesday, January 21st. Wall Street Zen raised shares of Smith & Nephew SNATS from a “buy” rating to a “strong-buy” rating in a report on Saturday, March 7th. Finally, Canaccord Genuity Group increased their price target on shares of Smith & Nephew SNATS from $34.00 to $35.00 and gave the company a “hold” rating in a research report on Thursday, March 5th. One investment analyst has rated the stock with a Strong Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $36.25.

Smith & Nephew SNATS Company Profile

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.